| The consensus molecular subtypes of colorectal cancer J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ... Nature medicine 21 (11), 1350-1356, 2015 | 4544 | 2015 |
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy A Sadanandam, CA Lyssiotis, K Homicsko, EA Collisson, WJ Gibb, ... Nature medicine 19 (5), 619-625, 2013 | 1072 | 2013 |
| MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ... Clinical cancer research 21 (9), 2057-2064, 2015 | 364 | 2015 |
| High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays N Brandenberg, S Hoehnel, F Kuttler, K Homicsko, C Ceroni, T Ringel, ... Nature biomedical engineering 4 (9), 863-874, 2020 | 271 | 2020 |
| T cell–induced CSF1 promotes melanoma resistance to PD1 blockade NJ Neubert, M Schmittnaegel, N Bordry, S Nassiri, N Wald, C Martignier, ... Science translational medicine 10 (436), eaan3311, 2018 | 266 | 2018 |
| Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma M Fankhauser, MAS Broggi, L Potin, N Bordry, L Jeanbart, AW Lund, ... Science translational medicine 9 (407), eaal4712, 2017 | 214 | 2017 |
| Standards of care and novel approaches in the management of glioblastoma multiforme AF Hottinger, R Stupp, K Homicsko Chinese journal of cancer 33 (1), 32, 2014 | 172 | 2014 |
| Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation … W Wick, T Gorlia, P Bady, M Platten, MJ Van Den Bent, MJB Taphoorn, ... Clinical cancer research 22 (19), 4797-4806, 2016 | 138 | 2016 |
| ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016 C Dittrich, M Kosty, S Jezdic, D Pyle, R Berardi, J Bergh, N El-Saghir, ... ESMO open 1 (5), e000097, 2016 | 133 | 2016 |
| Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy E Ghisoni, A Wicky, H Bouchaab, M Imbimbo, J Delyon, BG Moura, ... European Journal of Cancer 149, 153-164, 2021 | 98 | 2021 |
| Sphingolipids control dermal fibroblast heterogeneity L Capolupo, I Khven, AR Lederer, L Mazzeo, G Glousker, S Ho, F Russo, ... Science 376 (6590), eabh1623, 2022 | 79 | 2022 |
| A neutrophil response linked to tumor control in immunotherapy J Gungabeesoon, NA Gort-Freitas, M Kiss, E Bolli, M Messemaker, ... Cell 186 (7), 1448-1464. e20, 2023 | 77 | 2023 |
| Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. R Dienstmann, J Guinney, M Delorenzi, A De Reynies, P Roepman, ... Journal of Clinical Oncology 32 (15_suppl), 3511-3511, 2014 | 76 | 2014 |
| Turning tumors from cold to inflamed to improve immunotherapy response CL Gerard, J Delyon, A Wicky, K Homicsko, MA Cuendet, O Michielin Cancer treatment reviews 101, 102227, 2021 | 48 | 2021 |
| Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements HAR Homulle, F Powolny, PL Stegehuis, J Dijkstra, DU Li, K Homicsko, ... Biomedical optics express 7 (5), 1797-1814, 2016 | 40 | 2016 |
| Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by … E Cardoso, T Mercier, AD Wagner, K Homicsko, O Michielin, ... Journal of chromatography B 1083, 124-136, 2018 | 38 | 2018 |
| Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity A Chryplewicz, J Scotton, M Tichet, A Zomer, K Shchors, JA Joyce, ... Cancer Cell 40 (10), 1111-1127. e9, 2022 | 37 | 2022 |
| Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients K Homicsko, G Richtig, F Tuchmann, Z Tsourti, D Hanahan, G Coukos, ... Annals of Oncology 29, x40, 2018 | 37 | 2018 |
| Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages M Tichet, S Wullschleger, A Chryplewicz, N Fournier, R Marcone, ... Immunity 56 (1), 162-179. e6, 2023 | 35 | 2023 |
| Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors A Stathis, D Hess, R von Moos, K Homicsko, G Griguolo, M Joerger, ... Investigational new drugs 35, 766-772, 2017 | 33 | 2017 |
